Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice.
The effect of weekly treatments with various gammaglobulin preparations on the development of human B-cell tumors was studied in severe combined immunodeficient (SCID) mice. SCID mice were injected i.p. with human peripheral blood mononuclear cells (PBMCs) from an Epstein-Barr virus (EBV)-seropositive healthy blood donor. Repopulated SCID mice were divided into 7 treatment groups receiving either PBS, 2 commercial gammaglobulin preparations, purified IgG prepared from pooled plasma from EBV-seronegative or -seropositive blood donors, a rabbit anti-serum against EBV envelope glycoprotein gp340 or interferon (IFN)-alpha. All treatments started 1 day after injection of PBMC and continued for 8 weeks. In the PBS-treated control group, 85% of mice developed tumors in the abdominal cavity, mostly with liver metastasis within 150 days. Tumor formation was prevented by treatment with the 2 commercial gammaglobulin preparations as well as by purified IgG from EBV-seropositive donors. In contrast, purified IgG from EBV-seronegative donors, rabbit anti-gp340 anti-serum or IFN-alpha had no effect. Our results indicate that the effect of gammaglobulin is due to the presence of specific antibodies against EBV antigens. Further experiments showed that both the time of onset and the duration of treatment, as well as the dose of Ig, are important factors for prevention of tumor formation. Studies aiming at identification of target antigens for antibodies which prevent lymphoma development may be clinically relevant for prevention and possibly treatment of lympho-proliferative disease in severely immuno-compromised patients.
Abedi
M R
MR
Department of Immunology, Microbiology, Pathology and Infectious Diseases, Huddinge University Hospital, Sweden. m.abedi@impi.ki.se
Linde
A
A
Christensson
B
B
Mackett
M
M
Hammarström
L
L
Smith
C I
CI
D000008:Abdominal Neoplasms / Q000517:prevention & control / Q000821:virology; D000818:Animals; D000914:Antibodies, Viral / Q000627:therapeutic use*; D006566:Herpesviridae Infections / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000637:transplantation / Q000821:virology; D016393:Lymphoma, B-Cell / Q000517:prevention & control / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000517:prevention & control* / Q000821:virology; D051379:Mice; D016513:Mice, SCID; D011817:Rabbits; D013047:Specific Pathogen-Free Organisms; D014412:Tumor Virus Infections / Q000276:immunology; D014763:Viral Matrix Proteins / Q000276:immunology
D000914:Antibodies, Viral; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D016898:Interferon-alpha; D014763:Viral Matrix Proteins